Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Gain Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Gain Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.10M, up 13.9% year over year. For fiscal 2025 it was $10.21M, down 5.4% from the year before. The highest annual figure on record is $11.52M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.21M | -5.4% |
| FY2024 | Dec 31, 2024 | $10.79M | -6.3% |
| FY2023 | Dec 31, 2023 | $11.52M | +37.5% |
| FY2022 | Dec 31, 2022 | $8.38M | +16.9% |
| FY2021 | Dec 31, 2021 | $7.16M | +217.1% |
| FY2020 | Dec 31, 2020 | $2.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.14M | -22.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.76M | +22.4% |
| Q4 FY2025 | Dec 31, 2025 | $2.35M | +91.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.85M | +8.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.76M | -37.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.26M | -10.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.22M | -48.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.62M | +10.7% |
| Q2 FY2024 | Jun 30, 2024 | $4.44M | +11.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.51M | -10.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.37M | +4.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.37M | +20.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.99M | +54.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.79M | +79.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.27M | +54.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.96M | -20.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.58M | +44.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.56M | +9.5% |
| Q4 FY2021 | Dec 31, 2021 | $1.47M | +50.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.48M | +479.4% |
| Q2 FY2021 | Jun 30, 2021 | $1.79M | +308.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.42M | +240.7% |
| Q4 FY2020 | Dec 31, 2020 | $975.61K | – |
| Q3 FY2020 | Sep 30, 2020 | $427.47K | – |
| Q2 FY2020 | Jun 30, 2020 | $438.87K | – |
| Q1 FY2020 | Mar 31, 2020 | $417.26K | – |
See a number that looks wrong?